Galderma Laboratories, L.P. (Galderma) Internet Privacy Policy. Galderma respects the privacy of every individual visiting our Web sites. Galderma's Internet Privacy Policy, outlining the information Galderma collects and how Galderma uses such information, is as follows:


Personally Identifiable Information
Galderma collects personally identifiable information (such as name, address, telephone/fax number and e-mail address) only when voluntarily provided by a visitor to our Web sites. Galderma does not sell, rent or otherwise make available any personally identifiable information submitted by visitors to our Web site to any third parties. This information will not be used for any direct marketing or unsolicited follow-up unless we have previously informed you of this possible use and you have given us your express permission when submitting it. After obtaining your consent, Galderma may use this information for such purposes as:
  • Sending you paper publications or other correspondence
  • Sending you e-mail press releases or notification
  • Delivering goods or prizes

  • Only authorized Galderma staff or our agents (who have agreed to keep information secure) have access to personally identifiable information.


    Galderma does make use of non-personally identifiable statistical information collected from users (browser type, geographical location, age, gender) for optimization of its sites as part of its continual internal review process and in a general way to learn more about its clients. This information will not be disclosed to third parties by Galderma. This data will only be used for the stated purpose and will not be used for any unsolicited communication unless you give us permission.


    Log Files
    Galderma uses IP addresses to analyze trends, administer the site, track user's movements, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Cookies
    Galderma does use tracking technology (known as 'cookies') which deposits certain bits of information on your hard drive. Cookies allow us to track and target your interests to tailor our sites to suit your needs better.

    Children
    Children and young people under the age of 16 are requested to get permission from their parent or guardian before they submit personal data to Galderma Web sites. We do not knowingly collect or use personally identifiable information from children under the age of 13 without first obtaining verifiable consent from a parent of legal guardian. Should a child whom we know to be under the age of 13 send personally identifiable information to us, we will only use that information to respond directly to that child, seek parental consent or provide parental notice.

    Links
    Links from this site may take you to other sites. Please be aware that we are not responsible for the privacy practices of such other sites. We advise you to check their privacy policies yourself before submitting any personally-identifiable information.


    Changes
    By using this Web site, you signify your agreement to the terms and conditions of this Privacy Policy. If you do not agree to these terms and conditions, please do not disclose any personally identifiable information though this Web site. This policy may be modified from time to time, and changes will be communicated promptly on this page. Please contact us for more information on this policy.

    Please contact us for more information on this policy.
    webmaster@galderma.com
    Galderma Laboratories, L.P.




    *For insured patients only. Certain limitations apply. Click here for program details.
    Important Safety Information
    Indication: ORACEA® is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.